Revenue Breakdown
Composition ()
No data
Revenue Streams
Penumbra Inc (PEN) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Thrombectomy, accounting for 66.7% of total sales, equivalent to $236.42M. Another important revenue stream is Embolization and Access. Understanding this composition is critical for investors evaluating how PEN navigates market cycles within the Medical Equipment, Supplies & Distribution industry.
Profitability & Margins
Evaluating the bottom line, Penumbra Inc maintains a gross margin of 68.02%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 15.37%, while the net margin is 12.28%. These profitability ratios, combined with a Return on Equity (ROE) of 13.78%, provide a clear picture of how effectively PEN converts its operational activities into shareholder value.
Comparative Benchmarking
In the context of the broader market, PEN competes directly with industry leaders such as ALGN and MASI. With a market capitalization of $13.43B, it holds a significant position in the sector. When comparing efficiency, PEN's gross margin of 68.02% stands against ALGN's 65.32% and MASI's 59.95%. Such benchmarking helps identify whether Penumbra Inc is trading at a premium or discount relative to its financial performance.
